2019

• Lipp, I.et al. 2019. Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis. Human Brain Mapping (10.1002/hbm.24568)
• Harding, K.et al. 2019. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurology, pp. -. (10.1001/jamaneurol.2018.4905)
• Whittam, D. H.et al. 2019. Rituximab in neurological disease: principles, evidence and practice. Practical Neurology 19(1), pp. 5-10. (10.1136/practneurol-2018-001899)
• Harding, K.et al. 2019. Disease modifying therapy in MS: clinical outcomes of escalation versus early intensive treatment strategies. JAMA Neurology

2018

• Tallantyre, E. C., Robertson, N. P. and Jolles, S. 2018. Secondary antibody deficiency in neurology. Current Opinion in Allergy and Clinical Immunology 18(6), pp. 481-488. (10.1097/ACI.0000000000000485)
• Robertson, J. and Tallantyre, E. 2018. Nerve sheath tumours. Journal of Neurology 265(12), pp. 3034-3035. (10.1007/s00415-018-9098-y)
• Beesley, R.et al. 2018. Impact of the 2017 revisions to McDonald criteria on the diagnosis of Multiple Sclerosis. Multiple Sclerosis 24(13), pp. 1786-1787. (10.1177/1352458518778007)
• Harding, K.et al. 2018. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple Sclerosis and Related Disorders 25, pp. 186-191. (10.1016/j.msard.2018.08.001)
• Tallantyre, E.et al. 2018. How common is truly benign MS in a UK population?. Journal of Neurology, Neurosurgery and Psychiatry (10.1136/jnnp-2018-318802)
• Alsaeed, M.et al. 2018. Multiple sclerosis: long-term outcomes in ethnic minorities. analysis of a UK population-based registry. European Journal of Neurology 25(4), pp. 701-704. (10.1111/ene.13571)
• Tallantyre, E.et al. 2018. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. Journal of Neurology 265(5), pp. 1115-1122. (10.1007/s00415-018-8812-0)

2017

• Willis, M.et al. 2017. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neuroimmunology and Neuroinflammation 4(2), article number: E320. (10.​1212/​NXI.​0000000000000320)

2016

• Tallantyre, E. C. and Robertson, N. P. 2016. Continuous evolution of magnetic resonance imaging in multiple sclerosis. Journal of Neurology 263(4), pp. 835-837. (10.1007/s00415-016-8099-y)
• Tallantyre, E. C., Wardle, M. and Robertson, N. 2016. How to run a multiple sclerosis relapse clinic. Practical Neurology 16, pp. 62-69. (10.1136/practneurol-2015-001214)

2015

• Williams, O., Tallantyre, E. C. and Robertson, N. 2015. Traumatic brain injury: pathophysiology, clinical outcome and treatment. Journal of Neurology 262(5), pp. 1394-1396. (10.1007/s00415-015-7741-4)
• Tallantyre, E.et al. 2015. The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic. Multiple Sclerosis Journal 21(1), pp. 67-75. (10.1177/1352458514538333)
• Tallantyre, E. C. and Robertson, N. 2015. Acute stroke management. Journal of Neurology 262(1), pp. 239-242. (10.1007/s00415-014-7607-1)
• Thomas, R. H.et al. 2015. Why neurology? The career choices of current UK neurology trainees [Conference Abstract]. Journal of Neurology, Neurosurgery & Psychiatry 86(11), pp. e4.132. (10.1136/jnnp-2015-312379.42)

2013

• Tallantyre, E. C. and Robertson, N. 2013. Autism and intellectual disability. Journal of Neurology 260(3), pp. 936-939. (10.1007/s00415-013-6861-y)